A decade of targeted therapy for non-small cell lung cancer
Journal Title: Journal of Pulmonology and Respiratory Research - Year 2017, Vol 1, Issue 1
Abstract
Chemotherapy is one of the main treatment options for cancer. However, chemotherapeutic agents usually suffer from poor pharmaceutical properties that restrict their use. Targeted therapy drugs have been developed to specifically target changes in cancer cells that help these cells to grow. Such drugs often work when standard chemotherapeutic drugs do not, they often have less severe side effects and they are most often used for advanced cancers. The objective of this article is to give an overview about the 16 FDA-approved targeted therapy drugs to treat non-small cell lung cancer.
Authors and Affiliations
Khalid Abu Ajaj
Keywords
Related Articles
- EP ID EP560447
- DOI 10.29328/journal.jprr.1001005
- Views 22
- Downloads 0
Avoiding confusion in high flow oxygen therapy concepts
Oxygen therapy is the main supportive treatment in hypoxemic respiratory failure and has traditionally been delivered using low and high flow devices. However, the maximal flow rates that these devices can deliver are li...
Successful Therapy with intravenous gamma globulin in two children with postinfectious bronchiolitis obliterans
Bronchiolitis obliterans (BO) is an infrequent clinical syndrome characterized by the chronic obstruction of small airways due to fibrosis [1]. Intravenous immunoglobulin (IVIG) could be used for treatment while underlyi...
Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.i.d. in asthma patients: a 12-week pilot study
Two of the most recent LABA/ICS combinations for treatment of persistent asthma are Fluticasone furoate/Vilanterol 92/22 µg (Ellipta) and Beclomethasone dipropionate/Formoterol 100/6 µg (Nexthaler).
Successful treatment of late-onset pulmonary hypertension after atrial septal defect operation with macitentan: Our center experience
Background: Macitentan significantly improves pulmonary hemodynamics and survival in patients with primary pulmonary hypertension (PPH). Its beneficial effect, however, may be blunted due to the adverse impacts such as a...
COPD and low plasma vitamin D levels: Correlation or causality?
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death and its prevalence and incidence is also related to smoking behavior [1]. COPD is still a chronic inflammatory and progressive disease caus...